New to peptides? Start with the foundations ->
What it does - plain English
Cerebrolysin is a mixture of small peptides and amino acids extracted from pig brain tissue. It is not a single peptide but a defined extract, manufactured by EVER Pharma in Austria since the 1970s. Researchers use it for neuroprotection (protecting brain cells from damage during stroke or injury) and as a treatment adjunct for vascular dementia, Alzheimer's disease, and traumatic brain injury.
The mechanism is thought to mimic naturally-occurring neurotrophic factors - proteins your brain makes to keep neurons healthy and growing. Think of it as delivering the signals your brain sends to repair and maintain itself, from the outside.
Approved as a pharmaceutical in 50+ countries across Europe, Asia, and Latin America. Not approved by the FDA in the United States.
Status
A-tier internationally, B-tier US. The international evidence base is unusual for a peptide product: actual phase-3 trials, post-marketing surveillance over decades, and clinical use in stroke and cognitive-decline indications across multiple countries.
The US absence is a regulatory artifact, not a science problem. If you are researching cognitive peptides with the strongest evidence base, this is where the real data lives. The catch: sourcing it cleanly in the US is hard.
Legal status
Not FDA-approved in the United States. Approved as a prescription medication in Austria, Germany, China, Russia, Mexico, India, and 40+ other countries.
US patients sometimes obtain it via two routes, neither clean:
- International pharmacy import - some patients obtain prescriptions from doctors abroad and import for personal use. Legality varies by state and federal posture. This is a gray zone, not a clear path.
- Research peptide vendors - products sold under "Cerebrolysin" naming may not be the EVER Pharma branded extract. May not be authentic. Consumer protection: none.
The branded EVER Pharma product is what the trials use. Generics and "research grade" alternatives may not match.
Where to source
Two complicated paths. Neither is as clean as buying a compounding-pharmacy BPC-157.
- International pharmacy import - some US patients obtain prescriptions from doctors abroad and import for personal use. Legality varies by state. One path, many variables.
- Research peptide vendors - the products sold under "Cerebrolysin" naming may not be the EVER Pharma branded extract. Ask hard questions about sourcing and ingredient provenance. The COA standard here is "is this actually Cerebrolysin or a similar-but-different peptide blend."
A single-source vendor with documented EVER Pharma supply chain is the gold standard. Everything else requires more skepticism than usual. Subscribe below for vendor reviews when we have them.
Two studies worth reading
Stroke recovery RCT
Muresanu et al., "Cerebrolysin and Recovery After Stroke (CARS-1)", Stroke
208 patients with acute ischemic stroke. Cerebrolysin plus standard rehab outperformed standard rehab alone on motor function recovery at 90 days. The trial that anchors stroke-recovery use cases internationally.
Vascular dementia review
Cui et al., "Cerebrolysin for vascular dementia", Cochrane Database of Systematic Reviews
Cochrane systematic review - the gold standard format for evidence synthesis. Found Cerebrolysin produces measurable improvements in cognition for people with vascular dementia, though magnitudes are modest. Worth reading for an honest assessment of effect sizes.
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Broken down for normal humans.
Last reviewed · 2026·05·04 · Status reviewed weekly